Literature DB >> 2820827

Brain gamma-aminobutyric acid receptor binding is normal in rats with thioacetamide-induced hepatic encephalopathy despite elevated plasma gamma-aminobutyric acid-like activity.

J E Maddison1, P R Dodd, G A Johnston, G C Farrell.   

Abstract

Brain gamma-aminobutyric acid (GABA) receptor density, affinity, and function, and plasma GABA-like activity were determined in rats with acute hepatic encephalopathy induced by an intraperitoneal injection of thioacetamide. In addition, the effect of various stress factors on brain GABA binding was assessed. Plasma GABA-like activity was significantly increased in rats with thioacetamide-induced hepatic encephalopathy compared with rats injected with vehicle alone (1506 +/- 993 nM, n = 7 vs. 367 +/- 97 nM, n = 9, mean +/- SD; p less than 0.001). In contrast, there were no alterations in either brain GABA receptor binding or in GABA-enhanced benzodiazepine binding in rats with hepatic encephalopathy when compared with relevant controls. However, rats that had received intraperitoneal injections of thioacetamide or vehicle (0.15 M NaCl) had significantly more low-affinity GABA receptors than rats that had neither been injected nor handled before killing (8769 +/- 1101 vs. 2710 +/- 757 fmol/mg protein, mean +/- SEM, p less than 0.001). We concluded that stress factors appear to be important causes of altered brain GABA binding. Brain GABA receptor binding and function, however, are unaltered in rats with thioacetamide-induced hepatic encephalopathy despite elevated plasma GABA-like activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820827     DOI: 10.1016/0016-5085(87)90570-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

Review 1.  Animal models of fulminant hepatic failure.

Authors:  J Terblanche; R Hickman
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

Review 2.  Endogenous GABAergic modulators in the pathogenesis of hepatic encephalopathy.

Authors:  J D Rothstein; M Olasmaa
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

Review 3.  Pathogenesis of hepatic encephalopathy.

Authors:  L Zieve
Journal:  Metab Brain Dis       Date:  1987-09       Impact factor: 3.584

Review 4.  Supersensitivity of GABA-A receptors in hepatic encephalopathy.

Authors:  M Baraldi
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

5.  Flumazenil does not improve hepatic encephalopathy associated with acute ischemic liver failure in the rabbit.

Authors:  C C van der Rijt; R J de Knegt; S W Schalm; O T Terpstra; K Mechelse
Journal:  Metab Brain Dis       Date:  1990-09       Impact factor: 3.584

6.  Effect of acute thioacetamide administration on rat brain phospholipid metabolism.

Authors:  J Osada; H Aylagas; M J Mirõ-Obradors; C Arce; E Palacios-Alaiz; M Cascales
Journal:  Neurochem Res       Date:  1990-09       Impact factor: 3.996

Review 7.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

8.  Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil.

Authors:  H P Meyer; D A Legemate; W van den Brom; J Rothuizen
Journal:  Metab Brain Dis       Date:  1998-09       Impact factor: 3.584

9.  A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma-aminobutyric acid (GABA) binding.

Authors:  L Zieve; P Ferenci; D Rzepczynski; J Ebner; C Zimmermann
Journal:  Metab Brain Dis       Date:  1987-09       Impact factor: 3.584

10.  Postsynaptic gamma-aminobutyric acid receptors in hepatic coma following portacaval shunt and hepatic artery ligation in the rat.

Authors:  P Ferenci; L Zieve; J Ebner; C Zimmermann; D Rzepczynski
Journal:  Metab Brain Dis       Date:  1987-09       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.